Related Experiment Video
Updated: Jan 3, 2026

Use of Microscale Thermophoresis to Measure Protein-Lipid Interactions
Published on: February 10, 2022
MUC4-ErbB2 Oncogenic Complex: Binding studies using Microscale Thermophoresis
Maxime Liberelle1, Romain Magnez1, Xavier Thuru1
1Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000, Lille, France.
Abstract:
The MUC4 membrane-bound mucin is a large O-glycoprotein involved in epithelial homeostasis. At the cancer cell surface MUC4 interacts with ErbB2 receptor via EGF domains to promote cell proliferation and migration. MUC4 is highly regarded as a therapeutic target in pancreatic cancer as it is not expressed in healthy pancreas, while it is neoexpressed in early preneoplastic stages (PanINs). However, the association/dissociation constant of MUC4-ErbB2 complex is unknown. Protein-protein interactions (PPIs) have become a major area of research in the past years and the characterization of their interactions, especially by biophysical methods, is intensively used in drug discovery. To characterize the MUC4-ErbB2 interaction, we used MicroScale Thermophoresis (MST), a powerful method for quantitative protein interaction analysis under challenging conditions. We worked with CHO cell lysates containing either the transmembrane β subunit of MUC4 (MUC4β) or a truncated mutant encompassing only the EGF domains (MUC4EGF3+1+2). MST studies have led to the characterization of equilibrium dissociation constants (Kd) for MUC4β-ErbB2 (7-25 nM) and MUC4EGF3+1+2/ErbB2 (65-79 nM) complexes. This work provides new information regarding the MUC4-ErbB2 interaction at the biophysical level and also confirms that the presence of the three EGF domains of MUC4 is sufficient to provide efficient interaction. This technological approach will be very useful in the future to validate small molecule binding affinities targeting MUC4-ErbB2 complex for drug discovery development in cancer. It will also be of high interest for the other known membrane mucins forming oncogenic complexes with ErbBs at the cancer cell surface.
Insights
We quantified the MUC4-ErbB2 interaction using MicroScale Thermophoresis (MST). This biophysical method determined the dissociation constants (Kd) for MUC4-ErbB2 complexes, aiding cancer drug discovery.
Area of Science:
- Biophysics
- Molecular Biology
- Cancer Research
Background:
- MUC4, a membrane mucin, promotes cancer cell proliferation and migration by interacting with the ErbB2 receptor.
- MUC4 is a therapeutic target in pancreatic cancer due to its neoexpression in preneoplastic lesions.
- The quantitative binding affinity of the MUC4-ErbB2 complex was previously unknown.
Purpose of the Study:
- To characterize the MUC4-ErbB2 interaction using biophysical methods.
- To determine the equilibrium dissociation constants (Kd) for MUC4-ErbB2 complexes.
- To validate the role of MUC4's EGF domains in ErbB2 binding.
Main Methods:
- MicroScale Thermophoresis (MST) was employed for quantitative protein interaction analysis.
- Experiments utilized Chinese Hamster Ovary (CHO) cell lysates containing MUC4 variants (MUC4β and MUC4EGF3+1+2).
- Equilibrium dissociation constants (Kd) were measured for MUC4-ErbB2 complexes.
Main Results:
- The dissociation constants (Kd) for MUC4β-ErbB2 were determined to be 7-25 nM.
- The dissociation constants (Kd) for MUC4EGF3+1+2/ErbB2 were found to be 65-79 nM.
- The study confirmed that MUC4's three EGF domains are sufficient for efficient ErbB2 interaction.
Conclusions:
- This research provides novel biophysical insights into the MUC4-ErbB2 interaction.
- The findings support MUC4 as a target for cancer therapeutics, particularly in pancreatic cancer.
- The MST approach is valuable for validating small molecule binding affinities in cancer drug discovery targeting MUC4-ErbB2.

